<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780022</url>
  </required_header>
  <id_info>
    <org_study_id>PFO-Elderly</org_study_id>
    <nct_id>NCT04780022</nct_id>
  </id_info>
  <brief_title>Patent Foramen Ovale Closure in Older Patients</brief_title>
  <acronym>PFO-Elderly</acronym>
  <official_title>Patent Foramen Ovale Closure in Older Patients: A Collaborative Multicenter Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Toronto General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ottawa Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Boniface Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinico de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut universitaire de cardiologie et de pneumologie de Qu√©bec, University Laval</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Describe the baseline and procedural characteristics of older patients undergoing PFO&#xD;
           closure due to cryptogenic embolism.&#xD;
&#xD;
        -  Assess the long-term follow-up of this cohort, focusing on neurological events and their&#xD;
           origin, major cardiac outcomes, as well as survival rates and death origin.&#xD;
&#xD;
        -  Seek for predictors of neurological event recurrence after the procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with cryptogenic stroke, up to 4 randomized trials and subsequent meta-analyses&#xD;
      have recently shown a significant reduction in recurrent ischemic stroke events following&#xD;
      percutaneous closure of patent foramen ovale (PFO) . All randomized trials but one excluded&#xD;
      patients older than 60 years, and a mean patient age of about 50 years was reported in the&#xD;
      single randomized trial including older patients. Thus, whereas PFO closure has been&#xD;
      established as the new gold-standard therapy in young patients with cryptogenic stroke and&#xD;
      PFO, there are no definite recommendations on the management of patients older than 60 years.&#xD;
      Some studies have shown that older patients with cryptogenic stroke exhibit a much higher&#xD;
      prevalence of PFO (compared with patients with stroke of known cause), similar to that in&#xD;
      younger populations, but scarce data exist on acute and mid-term clinical outcomes of older&#xD;
      patients undergoing PFO closure.&#xD;
&#xD;
      The investigators have recently reported the results of study comparing the long-term&#xD;
      clinical outcomes of patients older (vs. younger) than 60 years in our centre. A total of 475&#xD;
      consecutive patients (90 older than 60 years) were included, and the main results can be&#xD;
      summarized as follows: 1) older patients with cryptogenic embolism and PFO exhibited a higher&#xD;
      burden of cardiovascular risk factors; 2) PFO closure was safe in older patients, with no&#xD;
      differences in periprocedural complications compared with younger patients; 3) at long-term&#xD;
      (median of 8 years) follow-up post-PFO closure, the global mortality rate was higher among&#xD;
      older patients, but differences were driven by noncardiovascular mortality (mainly cancer),&#xD;
      and 4) the rate of recurrent stroke/TIA was low (much lower than that predicted by the RoPE&#xD;
      score), but there was a tendency toward a higher incidence of recurrent stroke/TIA among&#xD;
      older patients, which appeared to be partially related to cardiovascular risk factor burden&#xD;
      (no differences in recurrent ischemic event rate were observed after adjustment for baseline&#xD;
      differences in cardiovascular risk factors between groups). The main limitation of this study&#xD;
      was the relatively low number of patients older than 60 years, precluding an appropriate&#xD;
      evaluation of the factors associated with poorer clinical outcomes in this population. Thus,&#xD;
      the investigators are planning to confirm prior findings in a collaborative project including&#xD;
      a much larger cohort of patients. Also, the results of this retrospective study would provide&#xD;
      the rationale for a CIHR submission on a randomized trial targeting this group of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of stroke</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of transient ischemic attack</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of peripheral embolism</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of deep venous thrombosis</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of atrial fibrillation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of myocardial infarction</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of bleeding</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of death</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Patent Foramen Ovale</condition>
  <condition>Ischemic Stroke</condition>
  <condition>Older People</condition>
  <arm_group>
    <arm_group_label>Older patients with cryptogenic embolism and PFO closure</arm_group_label>
    <description>Data (clinical events at last follow-up) on patients older than 60 years who have experienced a previous paradoxical embolism of unknown origin and underwent transcatheter PFO closure will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical events at last follow-up</intervention_name>
    <description>Clinical events (stroke, transient ischemic attack, peripheral embolism, deep venous thrombosis, atrial fibrillation, myocardial infarction, bleeding episode, death) at last follow-up</description>
    <arm_group_label>Older patients with cryptogenic embolism and PFO closure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients older than 60 years who have experienced a previous paradoxical embolism of&#xD;
        unknown origin and underwent transcatheter PFO closure.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients older than 60 years who have experienced a previous paradoxical embolism&#xD;
             (stroke, transient ischaemic attack or peripheral embolism) of unknown origin and&#xD;
             underwent transcatheter PFO closure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  PFO closure indication other than paradoxical embolism (example: platypnea orthodeoxia&#xD;
             syndrome).&#xD;
&#xD;
          -  Surgical PFO closure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Josep Rodes-Cabau, MD</last_name>
    <phone>418-656-8711</phone>
    <email>josep.rodes@criucpq.ulaval.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melanie Cote, MSc</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>2646</phone_ext>
    <email>melanie.cote@criucpq.ulaval.ca</email>
  </overall_contact_backup>
  <reference>
    <citation>S√∏ndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, Sj√∂strand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L; Gore REDUCE Clinical Study Investigators. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke. N Engl J Med. 2017 Sep 14;377(11):1033-1042. doi: 10.1056/NEJMoa1707404. Erratum in: N Engl J Med. 2020 Mar 5;382(10):978.</citation>
    <PMID>28902580</PMID>
  </reference>
  <reference>
    <citation>Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, B√©jot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Gu√©rin P, Piot C, Rossi R, Dubois-Rand√© JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G; CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017 Sep 14;377(11):1011-1021. doi: 10.1056/NEJMoa1705915.</citation>
    <PMID>28902593</PMID>
  </reference>
  <reference>
    <citation>Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, Tirschwell DL; RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. N Engl J Med. 2017 Sep 14;377(11):1022-1032. doi: 10.1056/NEJMoa1610057.</citation>
    <PMID>28902590</PMID>
  </reference>
  <reference>
    <citation>Lee PH, Song JK, Kim JS, Heo R, Lee S, Kim DH, Song JM, Kang DH, Kwon SU, Kang DW, Lee D, Kwon HS, Yun SC, Sun BJ, Park JH, Lee JH, Jeong HS, Song HJ, Kim J, Park SJ. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. J Am Coll Cardiol. 2018 May 22;71(20):2335-2342. doi: 10.1016/j.jacc.2018.02.046. Epub 2018 Mar 12.</citation>
    <PMID>29544871</PMID>
  </reference>
  <reference>
    <citation>Wintzer-Wehekind J, Alperi A, Houde C, C√¥t√© JM, Del Val D, C√¥t√© M, Rod√©s-Cabau J. Transcatheter closure of patent foramen ovale in patients older than 60 years of age with cryptogenic embolism. Rev Esp Cardiol (Engl Ed). 2020 Mar;73(3):219-224. doi: 10.1016/j.rec.2019.07.003. Epub 2019 Oct 1. English, Spanish.</citation>
    <PMID>31585849</PMID>
  </reference>
  <reference>
    <citation>Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, Di Angelantonio E, Di Tullio MR, Lutz JS, Elkind MS, Griffith J, Jaigobin C, Mattle HP, Michel P, Mono ML, Nedeltchev K, Papetti F, Thaler DE. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology. 2013 Aug 13;81(7):619-25. doi: 10.1212/WNL.0b013e3182a08d59. Epub 2013 Jul 17.</citation>
    <PMID>23864310</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec</investigator_affiliation>
    <investigator_full_name>Josep Rodes-Cabau</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

